Bortezomib will raise the amount or influence of flibanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Increased flibanserin adverse outcomes may come about if coadministered with many weak CYP3A4 inhibitors. Monitor for hepatitis B virus in all cancer clients starting off systemic treatment. Determine more details on hepatitis B https://carolem888frd2.blog-a-story.com/profile